Authors

Latest:

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Steven Horwitz, MD, presents the final results of the Phase 2 PRIMO trial, highlighting the efficacy and safety of duvelisib as a promising treatment option for relapsed/refractory peripheral T-cell lymphoma, with insights into overall response rates, progression-free survival, and adverse event management.

Steven M. Lipkin, MD, PhD

Latest:

Dr. Lipkin on Cancer Prevention Vaccine in Preclinical Model of Lynch Syndrome

Steven M. Lipkin, MD, PhD, the Gladys and Roland Harriman Professor of Medicine, professor of medicine in the Division of Gastroenterology and Hepatology, and vice chair for research in the Weill Department of Medicine at Weill Cornell Medicine; and a geneticist at NewYork-Presbyterian/Weill Cornell Medical Center, discusses a study of a cancer prevention vaccine in a preclinical model of Lynch syndrome during the 2019 AACR Annual Meeting

Steven P. Treon, MD, PhD, Dana-Farber Cancer Institute

Steven P. Treon, MD, PhD, Harvard Medical School

Steven R. Alberts, MD

Latest:

Dr. Alberts on Unmet Needs in CRC

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses unmet needs facing patients with colorectal cancer (CRC).

Steven T. Rosen, MD

Latest:

Dr. Rosen on the Emergence of Novel Therapies and Research With IO in Hematologic Malignancies

Steven T. Rosen, MD, Irell & Manella Cancer Center Director's Distinguished Chair, Morgan & Helen Chu Director's Chair of the Beckman Research Institute, provost and chief scientific officer, director of the Comprehensive Cancer Center, Beckman Research Institute, and Irell & Manella Graduate School of Biological Sciences, and professor in the Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope, discusses the emergence of novel therapies and the incorporation of immuno-oncology (IO) drugs in hematologic malignancies.

Steven Treon, MD, PhD

Latest:

Dr. Treon on Breakthroughs in WaldenstrÃ¶m's Macroglobulinemia

Steven Treon, MD, PhD, from the Dana-Farber Cancer Institute, discusses the game-changing discoveries in Waldenstrom's Macroglobulinemia that led to the approval of ibrutinib for treatment of the disease.

strong> Jessica K. Altman, MD, Northwestern University

Stuart Goldberg, MD

Latest:

Chasing the Holy Grail of EHR Interoperability

COTA Inc, an independent health care informatics company was founded to build research-grade, real-world data to exponentially improve outcomes and reduce costs—ensuring the right care for the right patient every time.

Stuart L. Goldberg, MD

Latest:

Dr. Goldberg on Financial Toxicities Faced in Hematology

Stuart L. Goldberg, MD, discusses financial toxicities faced in hematology.

Stuart L. Goldberg, MD, Rutgers

Stuart Lutzker, MD, PhD

Latest:

Dr. Lutzker on OX40 Agonist in Patients With Refractory Solid Tumors

Stuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.

Stuart M. Lichtman, MD

Latest:

Dr. Lichtman Discusses Supportive and Palliative Care

Dr. Stuart Lichtman, from Memorial Sloan-Kettering Cancer Center Commack, Explains the Benefits of Supportive and Palliative Care.

Sudipto Mukherjee, MD

Latest:

Dr. Mukherjee on Radioactive Iodine Treatment of Thyroid Cancer and Risk of MDS

Sudipto Mukherjee, MD, associate staff, Department of Hematology and Oncology, Cleveland Clinic, discusses a study examining the association between radioactive iodine treatment of thyroid cancer and the risk for developing myelodysplastic syndromes.

Sujana Movva, MD

Latest:

Dr. Movva on Molecular Profiling in Sarcoma

Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses a study presented at the 2014 ASCO Annual Meeting where researchers profiled more than 1900 sarcoma specimens to try to identify potential novel treatment modalities for patients with this disease.

Sujatha Nallapareddy, MD

Latest:

Dr. Nallapareddy on the Use of ctDNA Testing in Colorectal Cancer

Sujatha Nallapareddy, MD, gastrointestinal medical oncologist at Rocky Mountain Cancer Centers, discusses the use of circulating tumor DNA (ctDNA) testing in patients with colorectal cancer (CRC).

Sujit Sheth, MD, NewYork-Presbyterian Hospital/Weill Cornell Medical Center

Sukeshi R. Patel, MD

Latest:

Autophagy Modulation May Be a Novel Approach to Treatment of Advanced Cancers

Although prolonged autophagy can result in cancer cell death, recent investigations suggest that therapy-induced autophagy is a reversible response that promotes cancer cell survival, and thus may diminish the efficacy of some therapeutic agents.

Sukhmani Padda, MD

Latest:

Dr. Padda on Selecting a Therapy Following Osimertinib Resistance in NSCLC

Sukhmani K. Padda, MD, discusses treatment selection following osimertinib resistance in patients with non–small cell lung cancer.

Sukumar Nagendran, MD

Latest:

Dr. Nagendran on Family History, BRCA Status, and Risk

Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, discusses a study looking at patients' family history, BRCA mutation status, and breast cancer risk.